Clinical Trial Finder

• - Lymphoid Malignancies/Diseases:

  INCLUSION CRITERIA:

  - Patients with known lymphoid malignancy or precursor disease to a lymphoid malignancy, including multiple myeloma, B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL).

• - Confirmation of pathological diagnosis is required from the Laboratory of Pathology, NCI.

Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care or required testing on an NIH research protocol will be used for diagnosis.

• - Age greater than or equal to 18 years of age.

• - ECOG performance 0-2.

• - Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document NOTE: Patients enrolling with a.

LAR must be co-enrolled on another study. INCLUSION FOR APHERESIS: NOTE: This is optional in all patients and will only be requested if the patient is willing, timing allows, and the following criteria are met.

• - Hemoglobin greater than or equal to 10 mg/dL and platelet count greater than 75 K/uL.

• - Weight greater than 25 kilograms.

• - HIV negative.

• - Prothrombin Time - within normal limits.

• - Partial Thromboplastin Time - within normal limits.

• - Medically indicated central line in place or adequate peripheral venous access.

EXCLUSION CRITERIA:

• - Pregnant will not be eligible.

• - Active symptomatic major organ disorder that would increase the risk of biopsy or apheresis, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.

• - Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.

Non -Lymphoid MALIGNANCIES/DISEASES : The following criteria apply only to patients without a known lymphoid mali nancy or precursor disease, as described:

INCLUSION CRITERIA:

-Patients without a known lymphoid malignancy or lymphoid precursor diagnosis who have a planned surgical procedure during which blood or normal lymph node(s)/tissue (i.e., those not with pre-determined likelihood of abnormality/ malignancy) may be obtained for research studies as part of this protocol. Patient is appropriate to undergo the surgical procedure planned, and consented for the same, as needed. NOTE: This study will not evaluate eligibility of the patient for surgery.

• - Age >= 18 years of age.

• - Must be able and willing to sign informed consent 2.2.

2 Exclusion Criteria.

EXCLUSION CRITERIA:

• - Pregnant women will not be eligible.

• - Other active malignancy.

NOTE: Patients witha history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin as well as any in situ carcinoma are eligible. Patients with a malignancy that has been treated with curative intent and who are without evidence of disease for >=2 years will also be eligible at the discretion of the investigator.

• - Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretionof the principal investigator.

Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory investigations conducted in the Lymphoid Malignancies Branch, including analysis of cellular, molecular, genetic and genomic biology are attempting to develop new prognostic and diagnostic models, therapeutic agents and novel treatment approaches for lymphoid malignancies and pre-malignant conditions. Objectives: This biology protocol is designed to allow sample acquisition for use in the study of lymphoid malignancies and malignancy precursors, including but not limited to B and T cell malignancies, such as diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL) as well as comparison to tissues from patients without lymphoid disease. A variety of laboratory investigations will be conducted on blood, tumor, bone marrow, urine, abnormal fluid and normal tissue, including analysis of cellular, molecular, genetic and genomic biology in the support of NIH translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic models. Eligibility: Adult patients who meet the following:

• - Confirmed pathological diagnosis of lymphoid malignancy or lymphoid precursor, including B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL).

• - No known lymphoid malignancy or lymphoid precursor diagnosis and planning a surgical procedure during which blood or normal lymph node(s)/tissue (i.e., those not with pre-determined likelihood of abnormality/malignancy) may be obtained for research studies as part of this protocol.

Design: The purpose of this study is to examine, in an exploratory fashion, a variety of biologic assays relevant to the investigation of lymphoid malignancies. It is anticipated that up to 60 consented subjects will be studied each year. To account for these anticipated 60 consented subjects in addition to up to potentially 5 screen fails each year, an accrual ceiling of 650 consented subjects is planned over 10 years.

Arms

: 1

Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy

: 2

Patients without a known lymphoid malignancy or precursor disease to a lymphoid malignancy

Interventions